SHPH Form 4: Timothy Lorber Receives 54,094 RSUs with Staggered Vesting

Rhea-AI Filing Summary

Timothy J. Lorber, Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. (SHPH), was granted a total of 54,094 restricted stock units (RSUs) in transactions dated 08/08/2025. Each RSU represents a contingent right to receive one share of common stock and the grants were reported on a Section 16 Form 4.

The awards are split into two grants: 29,240 RSUs that vest one-third on each of 08/08/2026, 08/08/2027 and 08/08/2028, and 24,854 RSUs that vest on 02/08/2026. Both grants show an acquisition price of $0 and are held in a direct ownership form.

Positive

• CFO Timothy J. Lorber was granted a total of 54,094 RSUs (29,240 and 24,854) reported on 08/08/2025
• Each RSU represents the contingent right to one share of common stock, explicitly stated in the filing
• Vesting schedules are specified: one award vests one-third annually (08/08/2026, 08/08/2027, 08/08/2028) and the other vests on 02/08/2026
• Ownership form for both awards is direct (D), as reported in Table II

Negative

• None.

Insights

Compensation Analyst

TL;DR: CFO received 54,094 RSUs with defined vesting dates, split into two awards with multi-date vesting.

The filing discloses two RSU awards to CFO Timothy J. Lorber totaling 54,094 RSUs. One award of 29,240 RSUs vests in three equal installments on 08/08/2026, 08/08/2027 and 08/08/2028; the other 24,854 RSUs vests on 02/08/2026. The awards are reported as acquired at $0 and held directly. From a compensation-design perspective, the staggered vesting dates define timing for potential share issuance but the filing contains no details on grant rationale, target compensation levels, or performance conditions.

Corporate Governance Expert

TL;DR: Insider disclosure reports equity grants to an officer with explicit vesting schedule and direct ownership.

The Form 4 documents equity awards to an executive officer (CFO) and provides clear vesting dates and quantities: 29,240 RSUs with three-date vesting and 24,854 RSUs vesting on a single date. The form indicates direct beneficial ownership and $0 acquisition price. The disclosure meets Section 16 reporting requirements but does not include other governance details such as board approval language or equity plan identifiers within the provided text.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lorber Timothy J.

(Last) (First) (Middle)

C/O SHUTTLE PHARMACEUTICALS HOLDINGS

401 PROFESSIONAL DRIVE, SUITE 260

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Shuttle Pharmaceuticals Holdings, Inc. [ SHPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/08/2025		A		29,240		(2)	(2)	Common Stock	29,240	$0	29,240	D
Restricted Stock Unit	(1)	08/08/2025		A		24,854		(3)	(3)	Common Stock	24,854	$0	24,854	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU"s) represents the contingent right to receive one share of common stock.

2. One-third of these RSUs will vest on each of 08/08/2026, 08/08/2027 and 08/08/2028.

3. These RSUs will vest on 02/08/2026.

	/s/ Timothy J Lorber	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What RSU grants were reported for Shuttle Pharmaceuticals (SHPH) on this Form 4?

The filing reports grants totaling 54,094 RSUs to CFO Timothy J. Lorber: 29,240 RSUs and 24,854 RSUs.

When do the RSUs granted to Timothy J. Lorber vest?

The 29,240 RSUs vest one-third on 08/08/2026, 08/08/2027, and 08/08/2028. The 24,854 RSUs vest on 02/08/2026.

What is the reported acquisition price for the RSUs on the SHPH Form 4?

The reported acquisition price for the RSU awards is $0.

What is Timothy J. Lorber's relationship to Shuttle Pharmaceuticals (SHPH)?

The Form 4 identifies Timothy J. Lorber as an Officer with the title Chief Financial Officer.

Are the RSU awards held directly or indirectly according to the filing?

Both RSU awards are reported with ownership form Direct (D) in Table II.

What does each Restricted Stock Unit represent in this filing?

The filing states that each Restricted Stock Unit (RSU) represents the contingent right to receive one share of common stock.